A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

This study has been completed.

Study NCT00035061. Last updated on July 18, 2006. Information provided by Eli Lilly and Company

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
Official Title ^†
Brief Summary	Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
Detailed Description
Study Phase	Phase II
Study Type ^†	Interventional
Study Design ^†	Treatment
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Urologic Neoplasms Metastases, Neoplasm
Intervention ^†	Drug: pemetrexed
MEDLINE PMIDs
Links

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†
Start Date ^†
Completion Date
Eligibility Criteria ^†	Inclusion Criteria: You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. You must have at least one tumor that can be physically measured or scanned by x-ray. You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago. Exclusion Criteria: You may not have used an experimental medicine or device within the past month. Cancer that has spread to your brain. If you are unwilling or unable to take folic acid or vitamin B12 supplements.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States

Administrative Information Fields
NCT ID ^†	NCT00035061
Organization ID	4698
Secondary IDs ^††	H3E-MC-JMEU
Study Sponsor ^†	Eli Lilly and Company
Collaborators ^††
Investigators ^†
Information Provided By	Eli Lilly and Company
Verification Date	July 2006
First Received Date ^†	May 2, 2002
Last Updated Date	July 18, 2006

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.